Progress in PD-1/PD-L1 inhibitors combined with other approaches in the treatment of non-small cell lung cancer / 肿瘤

ABSTRACT

Recent insight into onco-immunology has led to the breakthrough in immunotherapy of non-small cell lung cancer (NSCLC). Specifically, the immune checkpoints such as programmed death-1 (PD-1)/ programmed death ligand-1 (PD-L1) have brought a new era in the treatment of NSCLC. To further improve the overall survival and benefit broader population, the multiple potential combinations with other therapeutic strategies based on PD-1/PD-L1 inhibitors are in clinical development. However, the screening of appropriate population, the monitoring of toxicity, and determination of the end point in the clinical trial are a series of challenges to be faced with. This article reviews the progress in PD-1/PD-L1 inhibitors as backbone to synergistically combine with the existing cancer treatments, including molecularly targeted therapy, chemotherapy, radiotherapy and other immunotherapy in NSCLC.